These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. Sharma S; Stolina M; Luo J; Strieter RM; Burdick M; Zhu LX; Batra RK; Dubinett SM J Immunol; 2000 May; 164(9):4558-63. PubMed ID: 10779757 [TBL] [Abstract][Full Text] [Related]
27. Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy. van Broekhoven CL; Parish CR; Demangel C; Britton WJ; Altin JG Cancer Res; 2004 Jun; 64(12):4357-65. PubMed ID: 15205352 [TBL] [Abstract][Full Text] [Related]
28. Listeriolysin O expressed in a bacterial vaccine suppresses CD4+CD25high regulatory T cell function in vivo. Nitcheu-Tefit J; Dai MS; Critchley-Thorne RJ; Ramirez-Jimenez F; Xu M; Conchon S; Ferry N; Stauss HJ; Vassaux G J Immunol; 2007 Aug; 179(3):1532-41. PubMed ID: 17641019 [TBL] [Abstract][Full Text] [Related]
29. Neutrophil-dependent tumor rejection and priming of tumoricidal CD8+ T cell response induced by dendritic cells overexpressing CD95L. Buonocore S; Haddou NO; Moore F; Florquin S; Paulart F; Heirman C; Thielemans K; Goldman M; Flamand V J Leukoc Biol; 2008 Sep; 84(3):713-20. PubMed ID: 18567840 [TBL] [Abstract][Full Text] [Related]
30. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination. Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294 [TBL] [Abstract][Full Text] [Related]
31. A novel strategy utilizing ultrasound for antigen delivery in dendritic cell-based cancer immunotherapy. Suzuki R; Oda Y; Utoguchi N; Namai E; Taira Y; Okada N; Kadowaki N; Kodama T; Tachibana K; Maruyama K J Control Release; 2009 Feb; 133(3):198-205. PubMed ID: 19000727 [TBL] [Abstract][Full Text] [Related]
32. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response. Strome SE; Voss S; Wilcox R; Wakefield TL; Tamada K; Flies D; Chapoval A; Lu J; Kasperbauer JL; Padley D; Vile R; Gastineau D; Wettstein P; Chen L Cancer Res; 2002 Mar; 62(6):1884-9. PubMed ID: 11912169 [TBL] [Abstract][Full Text] [Related]
33. Antigen presentation by exosomes released from peptide-pulsed dendritic cells is not suppressed by the presence of active CTL. Luketic L; Delanghe J; Sobol PT; Yang P; Frotten E; Mossman KL; Gauldie J; Bramson J; Wan Y J Immunol; 2007 Oct; 179(8):5024-32. PubMed ID: 17911587 [TBL] [Abstract][Full Text] [Related]
34. Freezing and thawing of bone marrow-derived murine dendritic cells with subsequent retention of immunophenotype and of antigen processing and presentation characteristics. Sai T; Milling SW; Mintz B J Immunol Methods; 2002 Jun; 264(1-2):153-62. PubMed ID: 12191518 [TBL] [Abstract][Full Text] [Related]
35. The Toll-like receptor 5 stimulus bacterial flagellin induces maturation and chemokine production in human dendritic cells. Means TK; Hayashi F; Smith KD; Aderem A; Luster AD J Immunol; 2003 May; 170(10):5165-75. PubMed ID: 12734364 [TBL] [Abstract][Full Text] [Related]
36. Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100. Xia DJ; Zhang WP; Zheng S; Wang J; Pan JP; Wang Q; Zhang LH; Hamada H; Cao X Gene Ther; 2002 May; 9(9):592-601. PubMed ID: 11973635 [TBL] [Abstract][Full Text] [Related]
37. Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity. He Y; Zhang J; Mi Z; Robbins P; Falo LD J Immunol; 2005 Mar; 174(6):3808-17. PubMed ID: 15749922 [TBL] [Abstract][Full Text] [Related]
38. Peripheral tolerance to a nuclear autoantigen: dendritic cells expressing a nuclear autoantigen lead to persistent anergic state of CD4+ autoreactive T cells after proliferation. Kawahata K; Misaki Y; Yamauchi M; Tsunekawa S; Setoguchi K; Miyazaki J; Yamamoto K J Immunol; 2002 Feb; 168(3):1103-12. PubMed ID: 11801644 [TBL] [Abstract][Full Text] [Related]
39. Antitumor immune response of dendritic cells (DCs) expressing tumor-associated antigens derived from induced pluripotent stem cells: in comparison to bone marrow-derived DCs. Iwamoto H; Ojima T; Hayata K; Katsuda M; Miyazawa M; Iida T; Nakamura M; Nakamori M; Iwahashi M; Yamaue H Int J Cancer; 2014 Jan; 134(2):332-41. PubMed ID: 23824921 [TBL] [Abstract][Full Text] [Related]
40. Efficient induction of specific cytotoxic T lymphocytes to tumor rejection peptide using functional matured 2 day-cultured dendritic cells derived from human monocytes. Tanaka F; Yamaguchi H; Haraguchi N; Mashino K; Ohta M; Inoue H; Mori M Int J Oncol; 2006 Nov; 29(5):1263-8. PubMed ID: 17016660 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]